Vedolizumab - Biologic Drug Details

Summary for vedolizumab

Tradenames:	2
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for vedolizumab

Recent Clinical Trials for vedolizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Therakos LLC	PHASE2
Universitaire Ziekenhuizen KU Leuven	PHASE4
Yale University	PHASE2

See all vedolizumab clinical trials

Pharmacology for vedolizumab

Mechanism of Action	Integrin Receptor Antagonists
Established Pharmacologic Class	Integrin Receptor Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for vedolizumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for vedolizumab Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,004,808		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,040,855		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,111,968		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	7,147,851		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	Injection	761133	10,004,808		DrugPatentWatch analysis and company disclosures
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	Injection	761133	10,040,855		DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for vedolizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,004,808	2036-07-20	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,040,855	2032-05-02	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,111,968	2036-08-10	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,143,752	2036-07-20	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,172,921	2035-06-23	Patent claims search
Takeda Pharmaceuticals U.s.a., Inc.	ENTYVIO	vedolizumab	For Injection	125476	10,273,252	2036-06-14	Patent claims search

Market Dynamics and Financial Trajectory for Vedolizumab

Last updated: March 10, 2026

What are the current market drivers for vedolizumab?

Vedolizumab, sold under the brand name Entyvio, is a biologic therapy indicated primarily for moderate to severe inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. Key market drivers include:

• Increasing prevalence of IBD: U.S. and European epidemiology data show rising cases—ulcerative colitis affects approximately 1 million in the U.S., Crohn’s disease about 780,000 (Molodecky et al., 2017). This growth fuels demand for effective therapies.
• Limited treatment options: Conventional therapies like corticosteroids and immunomodulators have variable efficacy and safety concerns. Vedolizumab offers a targeted mechanism with a favorable safety profile.
• Shifting treatment paradigms: The adoption of biologics over steroids and immunomodulators is expanding, especially in patients refractory to prior treatments.
• Regulatory approvals: Vedolizumab gained FDA approval in 2014 and EMA approval shortly after, enabling broader access.
• Market exclusivity: Patent protections, which extend until early 2030s, prevent generic competition, supporting revenue stability.

How does the competitive landscape influence vedolizumab?

Vedolizumab faces competition primarily from other biologics, including:

• Anti-TNF agents: Infliximab (Remicade), adalimumab (Humira), certolizumab (Cimzia).
• Integrin inhibitors: Natalizumab (Tysabri), which has a different safety profile.
• JAK inhibitors: Tofacitinib (Xeljanz), an oral option approved for ulcerative colitis.

Key differentiators:

• Mechanism of action: Vedolizumab selectively targets gut lymphocyte trafficking, reducing systemic immunosuppression. Its gut-selectivity diminishes risks like progressive multifocal leukoencephalopathy seen with natalizumab.
• Safety profile: Slightly better safety outcomes compared to anti-TNF agents in terms of infections and malignancies.
• Treatment persistence: Studies suggest higher persistence rates, indicating better long-term compliance.

What are the financial indicators for vedolizumab's trajectory?

Revenue Trends

Vedolizumab's global sales:

Year	Global Revenue (USD millions)	Growth Rate	Notes
2017	792	N/A	Initial launch year.
2018	1,471	85%	Rapid uptake post-launch.
2019	1,860	26.4%	Continued growth.
2020	2,389	28.2%	Rising demand amid COVID-19 challenges.
2021	2,744	14.9%	Moderate growth.

Market Share Analysis

In the IBD biologics segment:

• Vedolizumab: Approximately 19-22% of the global biologic IBD market (Evaluate Pharma, 2022).
• Anti-TNF agents: Compose 60% of sales, with infliximab leading.
• Other agents: Janus kinase inhibitors hold smaller shares.

Pricing and Reimbursement

• Average wholesale prices (AWP) range from USD 3,000 to USD 5,000 per infusion session.
• Reimbursement policies in major markets support sustained sales, with coverage largely aligned with clinical guidelines.

Future Financial Outlook

• Forecasted compound annual growth rate (CAGR): 10-12% through 2027 (Evaluate Pharma, 2022).
• Key growth factors: Expanded approved indications, increased market penetration, and potential biosimilar competition in the early 2030s.
• Risks: Patent expiry timelines, emerging competitors, and healthcare policy shifts.

What is the impact of regulatory and pipeline developments?

• New indications: In 2021, EMA approved vedolizumab for pediatric ulcerative colitis, opening new revenue streams.
• Pipeline developments: Trials examining vedolizumab’s efficacy in rheumatoid arthritis and Crohn's disease beyond current indications.
• Biosimilars: Patent expiration in the US expected around 2030. Biosimilar entrants could challenge pricing and market share.

Conclusions on market dynamics and financial trajectory

Vedolizumab establishes itself as a core biological for IBD management due to its targeted mechanism and safety profile. Revenue growth remains robust, driven by increasing disease prevalence, expanding indications, and a competitive position against other biologics. However, patent expiration and biosimilar entry pose long-term risks. Continued expansion into new indications and markets will be critical for sustaining growth.

Key Takeaways

• Rising IBD incidence supports demand for vedolizumab.
• It holds approximately 20% of the global IBD biologic market.
• Sales growth is projected at 10-12% CAGR through 2027.
• Patent protections extend until early 2030s; biosimilar competition looms.
• Expansion into pediatrics and additional indications offers future revenue opportunities.

Frequently Asked Questions

Q1: How does vedolizumab's safety profile influence its market position?
It reduces systemic immunosuppression risks, favoring long-term treatment adherence and patient retention.

Q2: When are biosimilars expected to enter the market?
In the US, patent expiry is around 2030, with biosimilars likely launching shortly thereafter.

Q3: What impact does the COVID-19 pandemic have on vedolizumab sales?
Sales showed resilience; infusion-based administration continued with safety measures, supporting ongoing revenue growth.

Q4: How are regulatory agencies influencing vedolizumab’s market access?
Approvals continue to expand for new indications, including pediatric uses, supporting market penetration.

Q5: What is the potential for vedolizumab in markets outside North America and Europe?
Growth opportunities exist in Asia-Pacific and Latin America, driven by rising IBD prevalence and increasing healthcare access.

---

References

[1] Molodecky, N. A., et al. (2017). Increasing incidence and prevalence of inflammatory bowel diseases with migration. Gastroenterology, 152(5), 1074-1081.

[2] Evaluate Pharma. (2022). Global Biologic Market Report. Retrieved from https://www.evaluate.com

[3] U.S. Food and Drug Administration. (2014). Entyvio (vedolizumab) approval press release.